Cycloset (quick-release formulation of bromocriptine mesylate), a dopamine D2 agonist, is a novel agent recently approved by the FDA for type 2 diabetes mellitus.
Magdalena Bryk-Gandera, BS
Advertisement
Articles by Magdalena Bryk-Gandera, BS
Advertisement
Latest Updated Articles
- Cycloset® (bromocriptine mesylate) Tablets: A Novel Treatment for the Management of Type 2 Diabetes in Adults
Published: May 5th 2011 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
States Push Forward on Insurance Mandates for GLP-1 and Obesity Treatments
2
FDA Expands Approval of Sotatercept-Csrk for Pulmonary Arterial Hypertension
3
Clinical Data Support Use of Low-Carbon Version of Albuterol Metered Dose Inhaler for Asthma
4
Study Shows Growing Confidence in Cell and Gene Therapies Across the Care Continuum
5
